Peking Hanmi Achieves 400 Billion Won in Annual Sales for the First Time... Cumulative Dividends of 138 Billion Won Returned to Group

Operating Profit of 77.7 Billion Won in 2025, 50% Dividend Payout Ratio
Dividend to Fund Hanmi Pharm’s R&D

Peking Hanmi Pharm, the Chinese subsidiary of Hanmi Pharm, recorded annual sales of 402.4 billion won and operating profit of 77.7 billion won in 2025, surpassing the 400 billion won mark for the first time since its establishment. The cumulative dividends paid to Hanmi Pharm since 2009 total approximately 138 billion won.

Front view of Beijing Hanmi Pharmaceutical. Hanmi Pharmaceutical

On May 8, Peking Hanmi Pharm announced these results and stated that it has approved a regular dividend payout totaling approximately 38.5 billion won (175 million yuan, with a payout ratio of 50%) for 2026. Of this, the portion attributable to Hanmi Pharm (with a 73.68% stake) amounts to about 28.4 billion won.

The dividend will be used as funding for Hanmi Pharm’s R&D and global business expansion. Last year, Hanmi Pharm received approximately 9 billion won in dividend income from Peking Hanmi Pharm.

Peking Hanmi Pharm is pursuing optimization of production processes and cost reduction in response to price reduction pressures, such as the Chinese government’s volume-based procurement (VBP) program. The company operates a sales and marketing network targeting about 9,000 hospitals and more than 200,000 healthcare professionals nationwide. Building on its existing core products (Litong, Ianping, and Yitanjing), it is expanding its pipeline into the chronic disease sector, including hypertension and diabetes.

A representative of Peking Hanmi Pharm stated, “We will continue stable growth through a product strategy that coexists with the local market and contribute to strengthening the group’s competitiveness.”

This content was produced with the assistance of AI translation services.